Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 12,238 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Dental Caries
Interventions: C16G2 Rinse, Placebo, C16G2 Gel; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Kalispell, Montana • Salt Lake City, Utah

Conditions: Neuropathic Pain, Pain
Interventions: Precision Spinal Cord Stimulation (SCS); Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Neovascular Age Related Macular Degeneration
Interventions: Physician-guided diagnostic; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more

Conditions: Covid19
Interventions: FB2001, FB2001 Placebo; Drug
Lead sponsor: Frontier Biotechnologies Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Myopia
Interventions: comfilcon A, samfilcon A; Device
Lead sponsor: CooperVision, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Whittier, California • Medina, Minnesota

Conditions: Coronary Arteriosclerosis
Interventions: Atorvastatin, Pravastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 36
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 30 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: CP-547,632; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions: Cytokine Induced Killer Cells; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Characteristics That Modify the Response to Cholecalciferol Treatment
Interventions: Vitamin D3, Placebo; Dietary Supplement · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Evanston, Illinois • Baltimore, Maryland + 2 more

Conditions: Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1, Neurogenic Claudication
Interventions: Pedicle Lengthening Osteotomy with Altum® Device, Control; Device
Lead sponsor: Innovative Surgical Designs; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions: Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids; Drug · Procedure
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Diabetic Ulcer
Interventions: Topical wound oxygen therapy, Topical wound oxygen Placebo; Device
Lead sponsor: AOTI Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions: There is no intervention in this study; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions: Omadacycline Oral Tablet, Placebo; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 17
States / cities: Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more

Conditions: No Evidence of Disease, Prostate Carcinoma
Interventions: Selenium, Placebo, Laboratory Biomarker Analysis, Pharmacological Study, Methylselenocysteine; Dietary Supplement · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois • Buffalo, New York • Nashville, Tennessee

Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
Interventions: FAZ053, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more

Conditions: Cancer
Interventions: [18F]fluoro-2-deoxy-D-glucose (FDG); Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Early Breast Cancer
Interventions: TALAZOPARIB; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 97
States / cities: Gilbert, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 64 more

Conditions: Obesity, Overweight, Chronic Weight Management
Interventions: Aleniglipron, Placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 3,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 64 more

Conditions: Multiple Sclerosis
Interventions: Active tDCS, sham tDCS; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Dental Caries, Dry Mouth, Periodontal Diseases, Bleeding Gum
Interventions: EHR Changes, Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training, Standard ADA Oral Health Training; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 55 Years and older
Enrollment: 929 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Opioid Overdose
Interventions: RELAY; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Resource information Supplemental Nutrition Assistance Program (SNAP), community health worker (CHW), medically tailored meals; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults

Optimized Programming in Spinal Cord Stimulation (SCS) System

NVAMD Satellite Study

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Individualized Response to Vitamin D Treatment Study

Pedicle Osteotomy for Stenosis Trial

A Study With Imlifidase in Anti-GBM Disease

Evaluation of Topical Wound Oxygen (two2) Therapy

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

A Multi-modality Imaging Assessment of Chemobrain

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

tDCS for the Management of Multiple Sclerosis Related Fatigue

Oral Health Intervention in Adult Primary Care

Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program

Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)